Nat Immunol:解开限制NK细胞的“枷锁” 找到肿瘤免疫治疗新方法

2016-05-28 佚名 生物谷Bioon.com

  众所周知,机体本身具有清除癌变细胞防止肿瘤形成的能力,但是一旦这一过程发生紊乱,癌症就会肆无忌惮地生长。 最近来自Walter and Eliza Hall研究所的研究人员对如何启动自然杀伤细胞(NK细胞)对抗癌症进行了深入研究。NK细胞是免疫系统的关键组成部分,能够在肿瘤形成之前或感染扩散之前检测并摧毁体内任何发生异常的细胞。但是这些发生异常的细胞有时会躲避开免疫系统的侦测

 

众所周知,机体本身具有清除癌变细胞防止肿瘤形成的能力,但是一旦这一过程发生紊乱,癌症就会肆无忌惮地生长。

最近来自Walter and Eliza Hall研究所的研究人员对如何启动自然杀伤细胞(NK细胞)对抗癌症进行了深入研究。NK细胞是免疫系统的关键组成部分,能够在肿瘤形成之前或感染扩散之前检测并摧毁体内任何发生异常的细胞。但是这些发生异常的细胞有时会躲避开免疫系统的侦测和攻击,并最终发展为癌症。

在这项最新研究中,研究人员在NK细胞中发现了一种“制动”蛋白,能够控制NK细胞摧毁肿瘤细胞的能力。在这项发表在Nature Immunology上的最新文章中,研究人员发现在小鼠模型体内清除这种“制动”蛋白,NK细胞能够更好地保护机体对抗转移性黑色素瘤。

NK细胞的激活依赖于IL-15,该研究表明NK细胞内部产生的这种叫做CIS的抑制性蛋白能够限制NK细胞对IL-15的应答,并进一步限制NK细胞对癌细胞的杀伤能力。研究人员首次发现了这种蛋白如何抑制NK细胞应答,他们希望能够开发出一种药物提高NK细胞对IL-15的应答,并帮助病人通过自身免疫系统对抗癌症。

Dr. Huntington这样说道:“这项研究介绍了应该如何激活病人体内的NK细胞,并通过促进免疫系统功能对付这种疾病。我们希望这项研究能够推动新型免疫疗法的开发,利用机体的NK细胞,将其维持在一个高度活跃的状态,这样能够更加有效并且更加特异地对抗癌症。”

原始出处:

CIS is a potent checkpoint in NK cell-mediated tumor immunity.

Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, Stannard K, Zhang JG, Teh C, Firth M, Ushiki T, Andoniou CE, Degli-Esposti MA, Sharp PP, Sanvitale CE, Infusini G, Liau NP, Linossi EM, Burns CJ, Carotta S, Gray DH, Seillet C, Hutchinson DS, Belz GT, Webb AI, Alexander WS, Li SS, Bullock AN, Babon JJ, Smyth MJ, Nicholson SE, Huntington ND.

Nat Immunol. 2016 May 23. doi: 10.1038/ni.3470. [Epub ahead of print]

相关会议推荐

2016(第七届)细胞治疗国际研讨会

会议时间:2016.06.17-2016.06.18     会议地点:武汉

会议详情: http://www.bioon.com/z/2016Cell-therapies/

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2083148, encodeId=65aa2083148e3, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Mon Oct 10 23:52:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881078, encodeId=ca6f18810e845, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Nov 05 15:52:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903135, encodeId=b2a6190313546, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 22 06:52:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138075, encodeId=2c8f1380e5fb, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:39:05 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2083148, encodeId=65aa2083148e3, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Mon Oct 10 23:52:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881078, encodeId=ca6f18810e845, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Nov 05 15:52:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903135, encodeId=b2a6190313546, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 22 06:52:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138075, encodeId=2c8f1380e5fb, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:39:05 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2016-11-05 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2083148, encodeId=65aa2083148e3, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Mon Oct 10 23:52:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881078, encodeId=ca6f18810e845, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Nov 05 15:52:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903135, encodeId=b2a6190313546, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 22 06:52:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138075, encodeId=2c8f1380e5fb, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:39:05 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2083148, encodeId=65aa2083148e3, content=<a href='/topic/show?id=79e264641cd' target=_blank style='color:#2F92EE;'>#治疗新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64641, encryptionId=79e264641cd, topicName=治疗新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Mon Oct 10 23:52:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881078, encodeId=ca6f18810e845, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Nov 05 15:52:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903135, encodeId=b2a6190313546, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 22 06:52:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138075, encodeId=2c8f1380e5fb, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:39:05 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

相关资讯

NK细胞具有抗流感病毒的功能

近年来,多种亚型(例如H1N1、H5N1及H7N9)流感病毒的世界范围内流行造成大量人群及牲畜的感染以及死亡。流感病毒感染宿主呼吸道内的多种细胞类型,如纤毛表皮细胞,I型与II型肺泡细胞以及各类免疫细胞。免疫细胞介导的吞噬与杀伤是清除流感病毒感染的重要方式之一,其中,天然免疫系统与适应性免疫系统均参与了这一过程。 NK细胞是天然免疫系统的重要组成部分,参与对多种病毒(如EB病毒EBV、巨细胞病毒

STM:人类NK细胞库多样性与病毒易感染相关

一项最新研究表明,人体NK细胞库与HIV感染风险有关。自然杀伤细胞(NK细胞)是一类常常受到忽视的免疫细胞。斯坦福大学的免疫学家Catherine Blish及其研究团队,通过CyTOF(mass cytometry)技术对人类NK细胞进行了研究。他们发现,人体NK细胞库越多样化,在接触到病毒的时候越容易感染HIV。研究人员根据NK细胞上的受体组合,将NK细胞分为大约三万个亚群。他们在体外培养人类

盘点:2014年Nature 杂志亮点研究成果

不知不觉,2014年马上就要过去了,迎接我们的将是崭新的2015年,2014年三大国际著名杂志Cell、Nature和Science(CNS)依然刊登了很多亮点耐人寻味的研究,本文中小编就盘点了2014年Nature杂志及其子刊发表的一些非常有意义的亮点研究。 Nature及其子刊 [1] Nature:新型线粒体荧光标记技术助力机体衰老研究 近日,来自中国的研究团队成功地

J Nutr Biochem:叶酸摄入量过多削弱机体免疫系统?

这项研究是由塔夫茨大学美国农业部人类营养研究中心(HNRCA)的研究人员进行的,研究结果发表在Nutritional Biochemistry。众所周知,孕妇的叶酸水平较低会增加婴儿神经管缺陷的风险。美国政府推荐民众叶酸摄入量为:孕妇600µg/天,普通民众400µg/天。 叶酸存在于许多天然食物中,例如绿叶蔬菜、豆类、鸡蛋、谷物和鱼等。此外,许多谷物富含叶酸。 机体每天都需要利用叶酸生成新的细胞

几种常见细胞治疗肿瘤技术:CART和NK细胞技术,其中taNK闪耀前景

免疫疗法是利用免疫系统来治疗疾病的一种概念:包括基于T细胞、B细胞及自然杀伤细胞(NK)等免疫细胞疗法。目前在CAR-T免疫疗法领域,除诺华及Juno外,其他跟进者包括Kite、基因治疗先驱蓝鸟生物(Bluebird bio)、生物技术巨头新基(Celgene),这些公司的细胞治疗技术皆是以T细胞为核心。一、CAR-T细胞CAR-T,全称是Chimeric Antigen Receptor T